#United States #California #Corporate Compliance #FTC Lawsuit #Hims & Hers

Hims & Hers Health Faces Stock Plunge

On July 29, 2026, the stock of Hims & Hers Health, Inc. (NYSE: HIMS) experienced a dramatic drop of approximately 14% after the Federal Trade Commission (FTC) initiated a lawsuit against the company over allegations of wrongful business practices. The swift market reaction reflected the seriousness of these claims, driving shares down to $25.00 each from the prior levels, leading many investors to reconsider their positions in the company.

Overview of Allegations

The FTC, joined by the State of Utah and the County of Los Angeles, has accused Hims & Hers of unsettling unethical behaviors regarding customer data privacy and subscription billing practices. These accusations, outlined in a hefty federal complaint filed in California, introduced significant concern among current and potential investors about the company's adherence to regulatory standards and its financial implications going forward.

Privacy Violations

Central to the FTC's allegations is the claim that Hims & Hers shared sensitive medical and personal health information of its users with external advertising companies, including major players like Meta Platforms and Snap. Despite extensive marketing assurances surrounding user confidentiality, the lawsuit details how Hims & Hers allegedly used tracking technologies to exploit user data covertly.

Subscription Issues

In addition to privacy concerns, the FTC's complaint raises alarms about the company's billing practices. Hims is alleged to have infringed the Restore Online Shoppers' Confidence Act (ROSCA) by signing consumers up for recurring subscriptions without informing them adequately. This included billing practices that began almost immediately after users filled out intake forms, well before they had received any medical consultation. The complaint highlights how Hims used obscure designs on its webpage intended to obfuscate cancellation options, effectively complicating the process for consumers who wished to terminate their subscriptions.

Investor Concerns and Investigations

In light of these serious allegations, Hagens Berman, a law firm renowned for its focus on corporate accountability, has launched an investigation into Hims & Hers. They are examining the company’s internal control systems to determine if they have been sufficiently robust in preventing violations and whether the financial reporting has accurately represented the potential regulatory fallout from these issues. Reed Kathrein, a partner at Hagens Berman, stated that there would be broader implications for investors if the allegations proved valid, especially relating to Hims' historically accurate financial disclosures.

Investors who believe they have incurred losses due to these developments are encouraged to come forward. The firm emphasizes the need for any insiders with information to assist in their investigation, hinting at potential rewards for whistleblowers through the SEC Whistleblower Program, which could include significant financial incentives.

Closing Thoughts

The events surrounding Hims & Hers Health serve as a crucial reminder of the importance of corporate governance and ethical practices in the digital health industry. As scrutiny increases and investigations unfold, stakeholders must stay informed of potential ramifications for investment and compliance. Investors are advised to monitor developments closely, as the outcome of this lawsuit could reshape the landscape not only for Hims but for the wider telehealth sector.

As this story continues to develop, more details will emerge regarding the findings and responses from Hims & Hers Health and its management team. The unfolding situation demonstrates the intricate balance between innovation in healthcare delivery and the stringent regulations designed to protect consumers.